XSHE
002727
Market cap1.08bUSD
Dec 05, Last price
13.07CNY
1D
0.31%
1Q
-12.63%
Jan 2017
-38.35%
IPO
35.23%
Name
Yixintang Pharmaceutical Group Co Ltd
Chart & Performance
P/E
66.93
P/S
0.42
EPS
0.20
Div Yield, %
3.06%
Shrs. gr., 5y
0.83%
Rev. gr., 5y
11.43%
Revenues
18.00b
+4.04%
Net income
114m
-79.23%
CFO
1.72b
-18.66%
Dividend
May 30, 20240.4 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yixintang Pharmaceutical Group Co., Ltd., together with its subsidiary, operates a chain of drugstores in China. It also produces and sells medicinal materials, Chinese herbal medicines, and food and health products, as well as engages in the drug distribution activities. As of January 31, 2020, the company operated 7,205 stores in Yunnan, Guizhou, Guangxi, Sichuan, Shanxi, Chongqing, Tianjin, Shanghai, Qiong, and other provinces and municipalities. It also sells products online. The company was formerly known as Yunnan Hongxiang Yixintang Pharmaceutical Co., Ltd. and changed its name to Yixintang Pharmaceutical Group Co., Ltd. in June 2019. Yixintang Pharmaceutical Group Co., Ltd. was founded in 2000 and is headquartered in Kunming, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||